Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 11 July 2017

Indication(s)

Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 3 more

Visit Chronic Obstructive Pulmonary Disease (COPD)

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 1 more

Visit Prostate Cancer

Related Content

More information

Category Value
Agency product number EMEA/H/C/002396
Orphan designation No
Date First Approved 24-02-2015
Type Medicinal product subject to medical prescription
Marketing authorisation holder Zambon S.p.A.
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions